{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-118476","form_type":"8-K","ticker":"CNMD","cik":"0000816956","company_name":"CONMED Corp","filed_at":"2025-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.254753+00:00","generated_at":"2026-05-16T14:26:59.768304+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CONMED to exit gastroenterology lines; terminates Gore VIABIL agreement effective Jan 1, 2026","bullets":["Gastroenterology product lines expected to generate $90M–$95M revenue in 2025 with ~45% gross margins.","Exit projected to cause EPS dilution of $0.45–$0.55 in 2026.","Consolidated gross margin expected to improve by ~80 bps after exit completion.","CONMED reaffirms full-year 2025 revenue guidance of $1.365B–$1.372B and adjusted EPS of $4.48–$4.53.","2026 guidance to be provided on Q4 2025 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-118476","json":"https://secwatch.observer/filing/0001213900-25-118476.json","markdown":"https://secwatch.observer/filing/0001213900-25-118476.md","text":"https://secwatch.observer/filing/0001213900-25-118476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/816956/000121390025118476/0001213900-25-118476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/816956/000121390025118476/ea0268554-8k_conmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:26:59.768304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}